Loss of SMAD4 expression occurs late in PDAC tumor progression [62] and is correlated with a higher metastatic burden [66], as well as malignant phenotypes of PDAC, including degree of differentiation, tumor size, and lymph node metastasis [67]. Here, SMAD4 is linked to neoplasm.